The ROE as of October 2024 (TTM) for Prometheus Biosciences, Inc. (RXDX) is -21.63%

According to Prometheus Biosciences, Inc.’s latest financial reports and current stock price. The company's current ROE is -21.63%. This represents a change of 94.35% compared to the average of -11.13% of the last 4 quarters.

Prometheus Biosciences, Inc. (RXDX) Historical ROE (quarterly & annually)

How has RXDX ROE performed in the past?

The mean historical ROE of Prometheus Biosciences, Inc. over the last ten years is -26.47%. The current -21.63% ROE has changed -18.29% with respect to the historical average. Over the past ten years (40 quarters), RXDX's ROE was at its highest in in the December 2020 quarter at 8.84%. The ROE was at its lowest in in the March 2017 quarter at -69.26%.

Prometheus Biosciences, Inc. (RXDX) ROE by Quarter and Year

Discovering the peaks and valleys of Prometheus Biosciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Prometheus Biosciences, Inc. (RXDX) Average ROE

How has RXDX ROE performed in the past?

The current ROE of Prometheus Biosciences, Inc. (RXDX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Prometheus Biosciences, Inc. (RXDX) ROE vs. Peers

How is RXDX’s ROE compared to its peers?

Prometheus Biosciences, Inc.’s ROE is greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than Akero Therapeutics, Inc. (-29.56%), greater than Immunovant, Inc. (-52.07%), greater than Madrigal Pharmaceuticals, Inc. (-95.61%), less than Roivant Sciences Ltd. (102.72%), less than Krystal Biotech, Inc. (13.36%), greater than 89bio, Inc. (-35.42%), greater than Pliant Therapeutics, Inc. (-41.05%), greater than Arcellx, Inc. (-12.42%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Viking Therapeutics, Inc. (-15.05%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), greater than Terns Pharmaceuticals, Inc. (-39.58%), less than Reata Pharmaceuticals, Inc. (19.32%), greater than IVERIC bio, Inc. (-38.66%), greater than Blueprint Medicines Corporation (-85.25%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Karuna Therapeutics, Inc. (-30.79%), greater than Day One Biopharmaceuticals, Inc. (-122.70%),

Build a custom stock screener for Prometheus Biosciences, Inc. (RXDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prometheus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Prometheus Biosciences, Inc. (RXDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Prometheus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.